Mireia Casulleras

Mireia Casulleras

Auto-generated profile, based on publicly available information

Mireia Casulleras

Biochemistry and Molecular Genetics Service, Hospital Clínic of Barcelona–IDIBAPS, CIBERehd, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Hepatology
Verified
Journal Article
Open access
IZIngrid Zhang
Ingrid Zhang
ACAnna Curto-Vilalta
Anna Curto-Vilalta
CLCristina López-Vicario
Cristina López-Vicario
MCMireia Casulleras
Mireia Casulleras
MDMarta Duran-Güell
Marta Duran-Güell
JCJoan Clària
Joan Clària
Patients with acute-on-chronic liver failure (ACLF) present a systemic hyperinflammatory response associated with increased circulating levels of small-molecule metabolites. To investigate whether these alterations reflect inadequate cell energy output, we assessed mitochondrial morphology and central metabolic pathways with emphasis on the tricarboxylic acid (TCA) cycle in peripheral leukocytes from patients with acutely decompensated (AD) cirrhosis, with and without ACLF. The study included samples from patients with AD cirrhosis (108 without and 128 with ACLF) and 41 healthy individuals. Leukocyte mitochondrial ultrastructure was visualized by transmission electron microscopy and cytosolic and mitochondrial metabolic fluxes were determined by assessing NADH/FADH2 production from various substrates. Plasma GDF15 and FGF21 were determined by Luminex and acylcarnitines by LC-MS/MS. Gene expression was analyzed by RNA-sequencing and PCR-based glucose metabolism profiler array. Mitochondrial ultrastructure in patients with advanced cirrhosis was distinguished by cristae rarefication and swelling. The number of mitochondria per leukocyte was higher in patients, accompanied by a reduction in their size. Increased FGF21 and C6:0- and C8:0-carnitine predicted mortality whereas GDF15 strongly correlated with a gene set signature related to leukocyte activation. Metabolic flux analyses revealed increased energy production in mononuclear leukocytes from patients with preferential involvement of extra-mitochondrial pathways, supported by upregulated expression of genes encoding enzymes of the glycolytic and pentose phosphate pathways. In patients with ACLF, mitochondrial function analysis uncovered break-points in the TCA cycle at the isocitrate dehydrogenase and succinate dehydrogenase level, which were bridged by anaplerotic reactions involving glutaminolysis and nucleoside metabolism. Our findings provide evidence at the cellular, organelle and biochemical levels that severe mitochondrial dysfunction governs immunometabolism in leukocytes from patients with AD cirrhosis and ACLF. Patients at advanced stages of liver disease have dismal prognosis due to vital organ failures and the lack of treatment options. In this study, we report that the functioning of mitochondria, which are known as the cell powerhouse, is severely impaired in leukocytes of these patients, probably as a consequence of intense inflammation. Mitochondrial dysfunction is therefore a hallmark of advanced liver disease.

21 October 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MCMireia Casulleras
Mireia Casulleras
RFRoger Flores-Costa
Roger Flores-Costa
MDMarta Duran-Güell
Marta Duran-Güell
JAJosé Alcaraz-Quiles
José Alcaraz-Quiles
SSSilvia Sanz
Silvia Sanz
JCJoan Clària
Joan Clària
Leukocyte endosomal trafficking plays a critical role in the anti-inflammatory actions of human albumin.

15 July 2022 in Hepatology
Verified
Journal Article
Open access
CLCristina López-Vicario
Cristina López-Vicario
DSDavid Sebastián
David Sebastián
MCMireia Casulleras
Mireia Casulleras
MDMarta Duran‐Güell
Marta Duran‐Güell
RFRoger Flores‐Costa
Roger Flores‐Costa
JCJoan Clària
Joan Clària
Background and Aim: Injury to hepatocyte mitochondria is common in metabolic dysfunction‐associated fatty liver disease. Here, we investigated whether changes in the content of essential fatty acid–derived lipid autacoids affect hepatocyte mitochondrial bioenergetics and metabolic efficiency. Approach and Results: The study was performed in transgenic mice for the fat‐1 gene, which allows the endogenous replacement of the membrane omega‐6–polyunsaturated fatty acid (PUFA) composition by omega‐3–PUFA. Transmission electron microscopy revealed that hepatocyte mitochondria of fat‐1 mice had more abundant intact cristae and higher mitochondrial aspect ratio. Fat‐1 mice had increased expression of oxidative phosphorylation complexes I and II and translocases of both inner (translocase of inner mitochondrial membrane 44) and outer (translocase of the outer membrane 20) mitochondrial membranes. Fat‐1 mice also showed increased mitofusin‐2 and reduced dynamin‐like protein 1 phosphorylation, which mediate mitochondrial fusion and fission, respectively. Mitochondria of fat‐1 mice exhibited enhanced oxygen consumption rate, fatty acid β‐oxidation, and energy substrate utilization as determined by high‐resolution respirometry, [1‐14C]‐oleate oxidation and nicotinamide adenine dinucleotide hydride/dihydroflavine‐adenine dinucleotide production, respectively. Untargeted lipidomics identified a rich hepatic omega‐3–PUFA composition and a specific docosahexaenoic acid (DHA)–enriched lipid fingerprint in fat‐1 mice. Targeted lipidomics uncovered a higher content of DHA‐derived lipid autacoids, namely resolvin D1 and maresin 1, which rescued hepatocytes from TNFα‐induced mitochondrial dysfunction, and unblocked the tricarboxylic acid cycle flux and metabolic utilization of long‐chain acyl‐carnitines, amino acids, and carbohydrates. Importantly, fat‐1 mice were protected against mitochondrial injury induced by obesogenic and fibrogenic insults. Conclusion: Our data uncover the importance of a lipid membrane composition rich in DHA and its lipid autacoid derivatives to have optimal hepatic mitochondrial and metabolic efficiency.

18 February 2022 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
MCMireia Casulleras
Mireia Casulleras
RFRoger Flores‐Costa
Roger Flores‐Costa
MDMarta Duran‐Güell
Marta Duran‐Güell
IZIngrid W. Zhang
Ingrid W. Zhang
CLCristina López‐Vicario
Cristina López‐Vicario
JCJoan Clària
Joan Clària
Albumin infusions are therapeutically used to revert hypoalbuminemia and to replace the extensively oxidized albumin molecule circulating in patients with acutely decompensated (AD) cirrhosis. Because albumin has high affinity for lipids, here we characterized the albumin lipidome in patients with AD and explored the albumin effects on the release of fatty acid (FA)–derived lipid mediators by peripheral leukocytes. Lipids and lipid mediators were measured by liquid chromatography–tandem mass spectrometry in albumin‐enriched and albumin‐depleted plasma fractions separated by affinity chromatography and in leukocyte incubations from 18 patients with AD and 10 healthy subjects (HS). Lipid mediators were also measured in 41 patients with AD included in an albumin therapy trial. The plasma lipidome associated with AD cirrhosis was characterized by generalized suppression of all lipid classes except FAs. In contrast to HS, albumin from patients with AD had lower content of polyunsaturated FAs (PUFAs), especially of the omega‐3‐PUFA docosahexaenoic acid. Consistent with this, the PUFA‐derived lipid mediator landscape of albumin from patients with AD was dominated by lower content of monohydroxy FA precursors of anti‐inflammatory/pro‐resolving lipid mediators (i.e., 15‐hydroxyeicosatetraenoic acid [15‐HETE]). In addition, albumin from patients with AD was depleted in prostaglandin (PG) E 2 , suggesting that this proinflammatory PG primarily travels disassociated to albumin in these patients. Incubation of leukocytes with exogenous albumin reduced PG production while inducing 15‐lipoxygenase expression and 15‐HETE release. Similar effects were seen under lipopolysaccharide plus N ‐formylmethionyl‐leucyl‐phenylalanine‐stimulated conditions. Finally, PG levels were lower in patients with AD receiving albumin therapy, whereas 15‐HETE was increased after albumin treatment compared with baseline. Conclusion: Our findings indicate that the albumin lipid composition is severely disorganized in AD cirrhosis and that administration of exogenous albumin has the potential to redirect leukocyte biosynthesis from pro‐inflammatory to pro‐resolving lipid mediators.

1 May 2026 in Hepatology
Verified
Journal Article
Open access
BCBryan J. Contreras
Bryan J. Contreras
BRBerta Romero-Grimaldo
Berta Romero-Grimaldo
MSMaría Belén Sánchez-Rodríguez
María Belén Sánchez-Rodríguez
MCMireia Casulleras
Mireia Casulleras
MDMarta Duran-GüeLl
Marta Duran-GüeLl
CLCristina López-Vicario
Cristina López-Vicario
Background & Aims: Patients with acutely decompensated cirrhosis (ADC) present severe immune dysfunction characterized by smoldering systemic inflammation and persistent immunosuppression rendering them at increased risk of bacterial infections and acute-on-chronic liver failure (ACLF). Approach & Results: We explored the profile of 98 immunomodulatory lipid mediators in ADC patients with and without ACLF and their effects on leukocyte function. We performed LC-MS/MS-based lipidomics of 308 plasma samples longitudinally collected from 93 ADC patients with and without ACLF and integrated expression and flow cytometry data with functional assays in leukocytes. Lipidomics identified the linoleic acid-derived leukotoxin 9,10-dihydroxy-12-octadecenoic acid (9,10-DiHOME) as the only lipid mediator elevated in ACLF. 9,10-DiHOME levels followed the disease severity course and peaked when patients acquired infections and developed ACLF. Leukocytes from ADC patients showed increased expression of soluble epoxide hydrolase (sEH), the enzyme responsible for 9,10-DiHOME biosynthesis. In polymorphonuclear leukocytes, 9,10-DiHOME impaired degranulation, phagocytosis, and respiratory burst capacities. In mononuclear leukocytes, this lipid mediator induced the expression of the immunosuppressive marker MerTK, impaired their ability to produce cytokines in response to LPS and disrupted mitochondrial dynamics and autophagic responses. Inhibition of sEH in vivo reduced immunosuppressive responses in peritoneal macrophages and significantly attenuated MerTK expression in liver macrophages. Conclusions: These findings indicate that increased levels of the leukotoxin 9,10-DiHOME weakens immune-cell defensive responses and position sEH as a potential drug target in ADC.